Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 677

Sort by

Sort Order Select

Journal Articles

Phase 2 study of inotuzumab ozogamicin for measurable residual disease in acute lymphoblastic leukemia in remission

Elias Jabbour, Fadi G. Haddad, Nicholas J. Short, Jayastu Senapati, Nitin Jain, Koji Sasaki, Jeffrey Jorgensen, Sa A. Wang, Yesid Alvarado, Xuemei Wang, Courtney DiNardo, Lucia Masarova, Tapan Kadia, Rebecca S. Garris, Farhad Ravandi, Hagop Kantarjian

Blood (2024) 143 (5): 417–421.

https://doi.org/10.1182/blood.2023022330

Published: 2024

Includes: Supplemental data

Journal Articles

Oral Decitabine/Cedazuridine with Venetoclax in High-Risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia: Analysis By Different Response Criteria

Blood (2023) 142 (Supplement 1): 3228.

https://doi.org/10.1182/blood-2023-189203

Published: 2023

Journal Articles

Deeper Insight into Splicing Mutations in Myelofibrosis

Julie Braish, Prithviraj Bose, Naveen Pemmaraju, Sherry Pierce, Koji Sasaki, Keyur P. Patel, Hagop Kantarjian, Lucia Masarova

Blood (2023) 142 (Supplement 1): 4580.

https://doi.org/10.1182/blood-2023-189168

Published: 2023

Journal Articles

Epigenetic Scarring Leads to Irreversible NK Cell Dysfunction in Myeloid Malignancies

Blood (2023) 142 (Supplement 1): 2088.

https://doi.org/10.1182/blood-2023-187626

Published: 2023

Journal Articles

Ponatinib Versus Imatinib in Patients with Newly Diagnosed Ph+ ALL: Subgroup Analysis of the Phase 3 Phallcon Study

Blood (2023) 142 (Supplement 1): 2871.

https://doi.org/10.1182/blood-2023-179537

Published: 2023

Journal Articles

Performance of the Molecular International Prognostic Scoring System (IPSS-M) in Hypomethylating Agent-Treated Patients with Myelodysplastic Syndromes

Blood (2023) 142 (Supplement 1): 1857.

https://doi.org/10.1182/blood-2023-189557

Published: 2023

Journal Articles

Protective Role of Oxaliplatin Among Platinum-Based Therapies in the Development of Therapy-Related Myeloid Neoplasms

Jeremy S Connors, Linda Zhang, Koji Sasaki, Courtney D. DiNardo, Nicholas J. Short, Naval Daver, Gautam Borthakur, Tapan M. Kadia, Hagop Kantarjian, Elias Jabbour, Margaret A Goodell, Guillermo Garcia-Manero, Koichi Takahashi

Blood (2023) 142 (Supplement 1): 4220.

https://doi.org/10.1182/blood-2023-190672

Published: 2023

Journal Articles

Phase I Study of the T-Cell Receptor-like Antibody, Hu8F4 in Patients with Relapsed and Refractory Myeloid Malignancies

Blood (2023) 142 (Supplement 1): 1545.

https://doi.org/10.1182/blood-2023-189966

Published: 2023

Journal Articles

Single-Cell Proteogenomics Analysis of AML Samples Treated with Decitabine and Venetoclax Reveals Divergent Treatment Escape Mechanisms

Blood (2023) 142 (Supplement 1): 2931.

https://doi.org/10.1182/blood-2023-190400

Published: 2023

Journal Articles

Minimal Residual Disease-Negative Complete Remission at the End of Induction Is a Prognostic Indicator of Long-Term Survival in Adult Patients with Ph+ Acute Lymphoblastic Leukemia Receiving First-Line Therapy

Ajibade Ashaye, Yves Chalandon, Hervé Dombret, Katherine Fazioli, Bingxia Wang, Ibrahim Aldoss, Fei Huang, Jessica T. Leonard, Nora Szabo, Conor McCloskey, Sunita Nair, Mehul Dalal, Meliessa Hennessy, Tammie Yeh, Talha Badar, Hagop Kantarjian, Josep-Maria Ribera, Elias Jabbour

Blood (2023) 142 (Supplement 1): 6075.

https://doi.org/10.1182/blood-2023-179645

Published: 2023

Journal Articles

Characterization of MDS and CMML Patients Harboring Trisomy 8 Abnormality: Clinical, Autoimmune, and Mutational Features

Hussain Alcassab, Koji Sasaki, Danielle E. Hammond, Alex Bataller, David B Beck, Tapan M. Kadia, Guillermo Montalban-Bravo, Kelly S. Chien, L. Jeffrey Medeiros, Hagop Kantarjian, Awdesh Kalia, Manjunath Nimmakayalu, Carlos E. Bueso-Ramos, Guillermo Garcia-Manero, Rashmi Kanagal-Shamanna

Blood (2023) 142 (Supplement 1): 1881.

https://doi.org/10.1182/blood-2023-190464

Published: 2023

Journal Articles

North American Blastic Plasmacytoid Dendritic Cell Neoplasm Consortium: position on standards of care and areas of need

Naveen Pemmaraju, Hagop Kantarjian, Kendra Sweet, Eunice Wang, Jayastu Senapati, Nathaniel R. Wilson, Marina Konopleva, Arthur E. Frankel, Vikas Gupta, Ruben Mesa, Matthew Ulrickson, Edward Gorak, Sumeet Bhatia, Tulin Budak-Alpdogan, James Mason, Maria Teresa Garcia-Romero, Norma Lopez-Santiago, Gabriela Cesarman-Maus, Pankit Vachhani, Sangmin Lee, Vijaya Raj Bhatt, William Blum, Roland B. Walter, Dale Bixby, Ivana Gojo, Madeleine Duvic, Raajit K. Rampal, Marcos de Lima, James Foran, Amir T. Fathi, Aric Cameron Hall, Meagan A. Jacoby, Jeffrey Lancet, Gabriel Mannis, Anthony S. Stein, Alice Mims, David Rizzieri, Rebecca Olin, Alexander Perl, Gary Schiller, Paul Shami, Richard M. Stone, Stephen Strickland, Matthew J. Wieduwilt, Naval Daver, Farhad Ravandi, Sumithira Vasu, Monica Guzman, Gail J. Roboz, Joseph Khoury, Muzaffar Qazilbash, Phyu P. Aung, Branko Cuglievan, Yazan Madanat, Mohamed A. Kharfan-Dabaja, Anna Pawlowska, Justin Taylor, Martin Tallman, Prajwal Dhakal, Andrew A. Lane

Blood (2023) 141 (6): 567–578.

https://doi.org/10.1182/blood.2022017865

Published: 2023

Journal Articles

The role of allogeneic transplant for adult Ph + ALL in CR1 with complete molecular remission: a retrospective analysis

Blood (2022) 140 (20): 2101–2112.

https://doi.org/10.1182/blood.2022016194

Published: 2022

Includes: Supplemental data

Journal Articles

Baseline Liver Elastography Does Not Predict Risks of Hepato-Toxicity to Reduced Dose Inotuzumab Therapy Combined with Minihcvd in B-Cell Acute Lymphoblastic Leukemia

Jayastu Senapati, Nicholas Short, Nitin Jain, Farhad Ravandi, Tharakeswara K. Bathala, Aram Bidikian, Fadi Haddad, Patrice Nasnas, Naval Daver, Tapan M. Kadia, Rebecca Garris, Monica Kwari, Hagop Kantarjian, Elias Jabbour

Blood (2022) 140 (Supplement 1): 3182–3184.

https://doi.org/10.1182/blood-2022-170931

Published: 2022

Journal Articles

Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN): Long-Term Outcomes and Novel Observations from a Large BPDCN Cohort

Naveen Pemmaraju, Hagop Kantarjian, Joseph D. Khoury, Nitin Jain, Muzaffar H Qazilbash, Sanam Loghavi, Sherry A. Pierce, Keyur P. Patel, Guillermo Garcia-Manero, Elias Jabbour, Naval Daver, Gautam Borthakur, Marina Konopleva

Blood (2022) 140 (Supplement 1): 1293–1294.

https://doi.org/10.1182/blood-2022-170956

Published: 2022

Journal Articles

Long Term Results of Phase 2 Study of Pegylated Interferon in Patients with Essential Thrombocythemia and Polycythemia Vera: Median Follow-up of 15 Years

Lucia Masarova, Prithviraj Bose, Naveen Pemmaraju, Mary Ann Richie, Gautam Borthakur, Zeev E. Estrov, Hagop Kantarjian, Keyur P. Patel, Srdan Verstovsek

Blood (2022) 140 (Supplement 1): 9683–9684.

https://doi.org/10.1182/blood-2022-165538

Published: 2022

Journal Articles

Impact of Spliceosome Mutations on the Prognosis of Myelodysplastic Syndrome (MDS)

Samuel Urrutia, Koji Sasaki, Rashmi Kanagal-Shamanna, Alex Bataller, Guillermo Montalban-Bravo, Irene Ganan-Gomez, Yue Wei, Hui Yang, Kelly S. Chien, Danielle Hammond, Carlos E. Bueso-Ramos, Sherry A. Pierce, Hagop Kantarjian, Guillermo Garcia-Manero

Blood (2022) 140 (Supplement 1): 6952–6954.

https://doi.org/10.1182/blood-2022-165488

Published: 2022

Journal Articles

Tagraxofusp, an Anti-CD123 Therapy, in Patients with Blastic Plasmacytoid Dendritic Cell Neoplasm and Prior or Concomitant Hematologic Malignancies: Subgroup Analysis of a Pivotal Trial

Naveen Pemmaraju, Marina Konopleva, Kendra Sweet, Anthony S. Stein, Sumithira Vasu, David A Rizzieri, Eunice S. Wang, Hagop Kantarjian, Christopher L. Brooks, Carole Paley, Tariq I. Mughal, Andrew A. Lane

Blood (2022) 140 (Supplement 1): 6155–6157.

https://doi.org/10.1182/blood-2022-159970

Published: 2022

Journal Articles

Del5q with One Additional Cytogenetic Abnormality Other Than Del20q Identifies a Higher Risk Population of MDS Patients

Robert E. Briski, Kelly S. Chien, Guillermo Montalban-Bravo, Tapan M. Kadia, Elias Jabbour, Naveen Pemmaraju, Koji Sasaki, Danielle Hammond, Nicholas Short, Farhad Ravandi, Yesid Alvarado, Sherry A. Pierce, Guillermo Garcia-Manero, Hagop Kantarjian

Blood (2022) 140 (Supplement 1): 4042–4044.

https://doi.org/10.1182/blood-2022-170029

Published: 2022

Journal Articles

Evaluation of Emergent FLT3 Mutations (FLT3m) at Relapse in Patients (Pts) with Wild-Type FLT3 Acute Myeloid Leukemia (AML)

Fadi Haddad, Georgio Medawar, Rashmi Kanagal-Shamanna, Hector Alvarez, Sanam Loghavi, Naval Daver, Sherry A. Pierce, Elias Jabbour, Tapan M. Kadia, Nicholas Short, Courtney D. DiNardo, Gautam Borthakur, Hussein A Abbas, Naveen Pemmaraju, Guillermo Garcia-Manero, Farhad Ravandi, Hagop Kantarjian, Musa Yilmaz

Blood (2022) 140 (Supplement 1): 3196–3198.

https://doi.org/10.1182/blood-2022-169991

Published: 2022

NARROW

Phase 2 study of inotuzumab ozogamicin for measurable residual disease in acute lymphoblastic leukemia in remission

Oral Decitabine/Cedazuridine with Venetoclax in High-Risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia: Analysis By Different Response Criteria

Deeper Insight into Splicing Mutations in Myelofibrosis

Epigenetic Scarring Leads to Irreversible NK Cell Dysfunction in Myeloid Malignancies

Ponatinib Versus Imatinib in Patients with Newly Diagnosed Ph+ ALL: Subgroup Analysis of the Phase 3 Phallcon Study

Performance of the Molecular International Prognostic Scoring System (IPSS-M) in Hypomethylating Agent-Treated Patients with Myelodysplastic Syndromes

Protective Role of Oxaliplatin Among Platinum-Based Therapies in the Development of Therapy-Related Myeloid Neoplasms

Phase I Study of the T-Cell Receptor-like Antibody, Hu8F4 in Patients with Relapsed and Refractory Myeloid Malignancies

Single-Cell Proteogenomics Analysis of AML Samples Treated with Decitabine and Venetoclax Reveals Divergent Treatment Escape Mechanisms

Minimal Residual Disease-Negative Complete Remission at the End of Induction Is a Prognostic Indicator of Long-Term Survival in Adult Patients with Ph+ Acute Lymphoblastic Leukemia Receiving First-Line Therapy

Characterization of MDS and CMML Patients Harboring Trisomy 8 Abnormality: Clinical, Autoimmune, and Mutational Features

North American Blastic Plasmacytoid Dendritic Cell Neoplasm Consortium: position on standards of care and areas of need

The role of allogeneic transplant for adult Ph + ALL in CR1 with complete molecular remission: a retrospective analysis

Baseline Liver Elastography Does Not Predict Risks of Hepato-Toxicity to Reduced Dose Inotuzumab Therapy Combined with Minihcvd in B-Cell Acute Lymphoblastic Leukemia

Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN): Long-Term Outcomes and Novel Observations from a Large BPDCN Cohort

Long Term Results of Phase 2 Study of Pegylated Interferon in Patients with Essential Thrombocythemia and Polycythemia Vera: Median Follow-up of 15 Years

Impact of Spliceosome Mutations on the Prognosis of Myelodysplastic Syndrome (MDS)

Tagraxofusp, an Anti-CD123 Therapy, in Patients with Blastic Plasmacytoid Dendritic Cell Neoplasm and Prior or Concomitant Hematologic Malignancies: Subgroup Analysis of a Pivotal Trial

Del5q with One Additional Cytogenetic Abnormality Other Than Del20q Identifies a Higher Risk Population of MDS Patients

Evaluation of Emergent FLT3 Mutations (FLT3m) at Relapse in Patients (Pts) with Wild-Type FLT3 Acute Myeloid Leukemia (AML)

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only